Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/5/2025 | $14.00 | Buy | H.C. Wainwright |
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
H.C. Wainwright resumed coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $14.00
HC Wainwright & Co. reiterated coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously
8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)
8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)
424B3 - Phio Pharmaceuticals Corp. (0001533040) (Filer)
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai
Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable safety and tolerability at all dose escalations King of Prussia, Pennsylvania--(Newsfile Corp. - January 20, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today a summary of the pathology results and safety outcomes across all cohorts in its Phase 1b dose escalation clinical trial with the INTASYL compound PH-762 for the treatment of skin cancer. A total of 22 patients with cutaneous carcinom
Registration Link for Phio's Presentation on Thursday, January 22 at 1:45 PM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. "All stakeholders and investors are invited to join the presentation and regist
SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)
SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)
SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)
Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai
King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment banking and asset management to his new role as Lead Independent Director. He was with JP Morgan for over 27 years, both in M&A and leading the Health Group in investment banking for his last 12 years there. Mr. Deming was appointed
Registration Link Below for October 28, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were reported in the o